On this 2022 World Pain Day, Unither Pharmaceuticals and Aptys Pharma are pleased to announce that the last of the 321 patients enrolled in their Metapain® phase III clinical trial has completed the study.
Metapain® is a fixed oral combination of 500 mg paracetamol and 30 mg nefopam for the treatment of moderate to severe pain, an aera where a non-opioid, non-NSAID, safe and effective treatment is eagerly awaited by doctors and patients.
This randomised, double-blind, controlled study compares the efficacy of the combination with that of each of the two components in a model of dental pain caused by the extraction of an impacted mandibular third molar. The patients were recruited from dental clinics in five different countries.
Results are expected early 2023.